Paras Health Panchkula Treats Deceptive Brain Tumour That Threatened 52-Year-Old Woman's Life Within Three Weeks

Paras Health Panchkula Treats Deceptive Brain Tumour That Threatened 52-Year-Old Woman's Life Within Three Weeks

Panchkula 29 June ( Ranjeet Singh Dhaaliwal ) : Doctors at Paras Health Panchkula, led by Dr. Ankit Amar Gupta, Consultant – Neurosurgery, successfully managed an exceptionally rare and aggressive brain tumour in a 52-year-old woman whose seemingly low-grade brain lesion transformed into a life-threatening malignant tumour within just three weeks. Timely diagnosis, advanced molecular evaluation and urgent neurosurgical intervention helped prevent a potentially fatal neurological outcome, highlighting the growing role of precision medicine in brain tumour management. The patient, Neelam, was admitted after experiencing a sudden generalized tonic-clonic seizure (GTCS), involving loss of consciousness and violent muscle contractions. An MRI revealed a small 1.5 cm contrast-enhancing lesion in the frontal region, with abnormalities extending into both frontal lobes and the corpus callosum. Based on imaging, doctors initially suspected either Primary Central Nervous System Lymphoma (PCNSL) or diffuse glioma. A stereotactic biopsy suggested a World Health Organization (WHO) Grade 2 diffuse glioma with a low Ki-67 proliferation index of around 3%, indicating a relatively slow-growing tumour. However, given the patient's age and the tumour's IDH-wildtype molecular profile, which is associated with aggressive behaviour, the neurosurgical team remained cautious despite the reassuring pathology.

Within the next three weeks, Neelam's condition deteriorated rapidly. She developed raised intracranial pressure, and an emergency MRI revealed explosive tumour progression into a large basifrontal mass with central necrosis. The tumour had spread across the corpus callosum in a characteristic butterfly pattern and had encased the anterior cerebral arteries, placing her at imminent risk of severe neurological complications. Recognising the rapid progression, the multidisciplinary team performed an emergency craniotomy with tumour decompression. The surgery successfully relieved pressure on the brain and enabled safe removal of the tumour despite its highly complex location. Commenting on the case, Dr. Ankit Amar Gupta, Consultant – Neurosurgery, Paras Health Panchkula, said, "This case highlights why brain tumours cannot always be judged solely by their initial biopsy appearance. Although the tumour initially resembled a low-grade glioma with a very low Ki-67 index, its molecular profile indicated far more aggressive biology. Within just three weeks, it progressed into what we clinically recognised as a molecular glioblastoma. Early suspicion, close monitoring and timely surgery were critical in preventing a potentially fatal outcome. Modern neuro-oncology increasingly depends on integrating imaging, pathology and molecular markers rather than histology alone. IDH-wildtype diffuse gliomas in older adults require heightened vigilance, even when microscopic findings appear deceptively benign."

Diffuse gliomas are among the most challenging brain tumours because some may appear low-grade under the microscope while harbouring aggressive molecular alterations that drive rapid progression. Advances in molecular diagnostics now help identify patients who require urgent surgery and comprehensive cancer treatment even when conventional pathology suggests a lower-grade tumour. Commenting on the successful outcome, Dr. Pankaj Mittal, Facility Director, Paras Health Panchkula, said, "At Paras Health Panchkula, we combine advanced diagnostics, multidisciplinary expertise and timely intervention to deliver the best possible outcomes for patients with complex neurological conditions. This case demonstrates the importance of precision medicine and coordinated care in managing highly aggressive brain tumours while bringing world-class neuroscience services closer to patients across the region." The successful management of this case underscores the evolving role of molecular neuro-oncology in improving outcomes for aggressive brain tumours. It also reinforces the importance of seeking prompt medical evaluation for seizures, persistent headaches or other unexplained neurological symptoms, where timely diagnosis and treatment can be lifesaving.